Seroatlas · Human Serome Atlas

SIGLEC15

Sialic acid-binding Ig-like lectin 15

Also known as: CD33L3, HsT1361, SIG15_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6ZMC9
Gene: SIGLEC15
Ensembl: ENSG00000197046
Chromosome: 18
Canonical length: 328 aa
Protein class: Predicted membrane proteins
Subcellular location: Nucleoplasm,Golgi apparatus

OverviewNCBI Gene

Predicted to be involved in regulation of actin cytoskeleton organization; regulation of bone resorption; and regulation of osteoclast development. Predicted to be located in membrane. Predicted to be part of protein-containing complex. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

328 residues, UniProt reviewed canonical sequence.

>Q6ZMC9|SIGLEC15
     1  MEKSIWLLAC LAWVLPTGSF VRTKIDTTEN LLNTEVHSSP AQRWSMQVPP EVSAEAGDAA
    61  VLPCTFTHPH RHYDGPLTAI WRAGEPYAGP QVFRCAAARG SELCQTALSL HGRFRLLGNP
   121  RRNDLSLRVE RLALADDRRY FCRVEFAGDV HDRYESRHGV RLHVTAAPRI VNISVLPSPA
   181  HAFRALCTAE GEPPPALAWS GPALGNSLAA VRSPREGHGH LVTAELPALT HDGRYTCTAA
   241  NSLGRSEASV YLFRFHGASG ASTVALLLGA LGFKALLLLG VLAARAARRR PEHLDTPDTP
   301  PRSQAQESNY ENLSQMNPRS PPATMCSP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SIGLEC15 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.43
Highest tissue expression: 2.8 nTPM

Expression across tissuesHPA

Tissue

small intestine: 2.8 nTPM
breast: 1.6 nTPM
duodenum: 1.3 nTPM
stomach: 1.2 nTPM
urinary bladder: 1.2 nTPM
spleen: 0.9 nTPM

Single-cell type

hofbauer cells: 18 nCPM
parietal cells: 12 nCPM
breast hormone-responsive cells: 6.6 nCPM
urothelial cells: 5 nCPM
epicardial cells: 4.5 nCPM
cardiomyocytes: 3.3 nCPM

Immune cell

classical monocyte: 3 nTPM
myeloid DC: 1 nTPM
total PBMC: 0.9 nTPM
intermediate monocyte: 0.3 nTPM
basophil: 0 nTPM
eosinophil: 0 nTPM

Brain region

cerebellum: 2.7 nTPM
basal ganglia: 2.2 nTPM
cerebral cortex: 2 nTPM
amygdala: 1.7 nTPM
white matter: 1.7 nTPM
hippocampal formation: 1.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.87
gnomAD pLI: 0
gnomAD missense Z: 0.98
DepMap mean gene effect: 0.03
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SIGLEC15 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SIGLEC15 as an antibody target. Whether an autoantibody or antibody against SIGLEC15 could matter depends on whether native SIGLEC15 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SIGLEC15 is annotated at the cell surface, where native SIGLEC15 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SIGLEC15 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...